Mucosal surfaces are a major portal of entry for many human pathogens that are the cause of infectious diseases worldwide.
INTRODUCTION: BIGGER ON THE INSIDE
The adult human mucosa lines the surfaces of the digestive, respiratory, and genitourinary tracts, covering an immense surface area (400 m 2 ) that is ∼200 times greater than that of the skin (1, 2) . It is estimated that 70% of infectious agents enter the host by mucosal routes (1) . Intense immunological activity occurs at these surfaces, where constant immune surveillance provides information about the external environment to the specialized mucosal immune system that has evolved to protect these surfaces. The mucosal immune system consists of an integrated network of tissues, lymphoid and nonlymphoid cells, and effector molecules such as antibodies, chemokines, and cytokines (3) . These host factors respond to pathogen invasion and infection (and to mucosal vaccines) by orchestrating innate and adaptive immune responses to confer protection. Initiation of antigen-specific immune responses occurs in organized mucosa-associated lymphoid tissue (MALT), which is characterized by the presence of numerous lymphoid follicles covering regions of the intestinal tract (Peyer's patches) and respiratory tract (bronchus-associated lymphoid tissues, referred to as BALT). The genitourinary tract lacks MALT, and priming of adaptive immune responses occurs exclusively within mucosa-draining lymph nodes (4, 5) . The organization of mucosal immune tissues and cells is unique from that of the systemic immune system and differs at the various mucosal tissues (Figure 1) . Understanding how these differences translate into immunological function is key to the rational design of prophylactic vaccines to protect against mucosal infections. 
Figure 1
Features of type I and type II mucosal tissue. Type I and type II mucosae are distinguished by the type of epithelium, the transport mechanisms for immunoglobulins, the presence of organized lymphoid tissue (mucosa-associated lymphoid tissue, known as MALT), and the composition of local immune cells. Type I mucosae are represented by surfaces of the lung and gut, whereas type II mucosae include surfaces of the mouth, esophagus, and cornea. The female genital tract has mucosal surfaces representative of both type I (endocervix, uterus) and type II (vagina, ectocervix) mucosae. Simple columnar epithelium linked by tight junctions covers the surfaces of type I mucosae, whereas type II mucosae are lined with stratified squamous epithelium. Beneath the type I epithelial layer are organized lymphoid structures (MALT). Microfold cells are present in the epithelium covering the MALT. Type I mucosal epithelia express polymeric immunoglobulin receptor on their basolateral surfaces, which binds to dimeric immunoglobulin A secreted by plasma cells in the lamina propria. Secretory IgA is exported transepithelially into the lumen of type I mucosal tissue and is the main protective immunoglobulin at these sites. Immunoglobulin G is the main protective immunoglobulin of type II mucosal surfaces. Dendritic cells (DCs) are found throughout the MALT and can present antigens locally or migrate to draining lymph nodes. Type II mucosal tissue lacks MALT at steady state, and DCs within and beneath the stratified epithelium must migrate to draining lymph nodes to present antigens to naïve lymphocytes. Type I and type II mucosae are also distinguished by the specific chemokines that are constitutively expressed by these tissues (4) . Abbreviations: HEV, high endothelial venules; SED, subepithelial dome.
cornea. The female genital tract has both type I (endocervix, uterus) and type II (vagina, ectocervix) mucosae. Type I and type II mucosae are also distinguished by the type of epithelium, the transport mechanisms for immunoglobulin A (IgA), the presence of organized lymphoid tissue (MALT), and the composition of local immune cells. In type I mucosal tissue, we can further distinguish diffuse lymphoid tissues, which are mainly associated with effector responses (cellular and antibody responses), from the organized lymphoid tissues, where most mucosal immune responses are initiated. Diffuse lymphoid tissue is composed mainly of lymphocytes residing as intraepithelial lymphocytes in the mucosal epithelium. In addition, numerous lymphocytes are present in the lamina propria, which is the connective tissue directly underlying the mucosal epithelium. These include mainly CD4 + T lymphocytes but also an important population of plasma cells, which are B lymphocytes that have developed into highly efficient factories for producing antibodies. Locally produced or transudate IgG is the primary protective immunoglobulin of type II mucosal surfaces (4) . In contrast, IgA is the main immunoglobulin in type I mucosal tissues (6) and is secreted as a dimer across the mucosal epithelium by an active transport mechanism using the polymeric Ig receptor (pIgR) (7) . Secretory IgA (sIgA) is a critical component in mucosal effector function. It is largely protease resistant and can therefore bind and neutralize pathogens or toxins in the gut despite the presence of active digestive enzymes. Neutralized pathogens are eliminated from the body along with digestive wastes. A significant amount of IgA is lost by secretion and elimination through the digestive tract. To maintain levels adequate for mucosal protection, IgA is one of the most abundantly produced proteins in the body. In both the airways and intestine, sIgA provides the first barrier to invasion by pathogens, so induction of potent IgA responses is an important goal of mucosal vaccination.
To induce effective mucosal immune response, a vaccine should be directed toward the main sites of mucosal immune activation. Inductive sites of the mucosal immune system include the organized lymphoid tissues such as the tonsils in the upper airway and the Peyer's patches and appendix in the intestines. These organized lymphoid tissues reside directly below the mucosal epithelium. Smaller versions of these nodules are also found in the larger airways as bronchusassociated lymphoid tissue and scattered along the intestines as isolated lymphoid follicles. The organized lymphoid tissues are similar to peripheral lymph nodes, but they show a much greater proportion of B lymphocytes relative to T lymphocytes. Moreover, most B cell isotype switching of naïve IgM + cells to IgA production occurs in these tissues (6, 8, 9) . Peripheral lymph nodes rely on activated dendritic cells (DCs) that migrate from peripheral sites to present antigens and prime lymph node resident lymphocytes. In contrast, antigen presentation and lymphocyte priming in type I mucosal tissue can occur in the local MALT through the function of mucosal DCs (10, 11) or epithelial microfold cells (M cells) (12, 13) . M cells are the most accessible targets for antigen delivery in the mucosal lumen. These cells are specialized for the capture and transport of microparticles by transcytosis to underlying lymphoid cells. To perform their transcytosis function, M cells phenotypically differ from the typical mucosal epithelial cell (i.e., absorptive enterocyte). For example, M cells lack an organized brush border or cilia (14, 15) and have a basolateral pocket that facilitates direct contact with B cells and CD4 + T cells. Owing to the lack of brush border, M cells are efficient in their surveillance of the mucosal lumen, from where they capture and transcytose viruses and bacteria and deliver them to the underlying immune cells. The transcytosed antigens are handed off either to follicular B cells to activate their responses or to mucosal DCs that can present antigens to T cells in the MALT or migrate to mesenteric lymph nodes. In sum, because of their key role in antigen delivery across the epithelial barrier, M cells play a pivotal role in triggering mucosal immune responses and are probably an ideal target for mucosal vaccine delivery.
Bridging Mucosal Innate and Adaptive Immunity
Immune responses are generally categorized into innate and adaptive immune arms, and the main distinction between the two lies in the nature of immune recognition and recall responses. T and B lymphocytes mediate adaptive immune responses utilizing antigen receptors that are clonally distributed and produced through rearrangement of antigen receptor gene segments in the genome. Lymphocytes with antigen-specific receptors expand by proliferation and provide enhanced responses ("memory") to repeat exposure to the same antigen. By contrast, innate immunity is dependent on receptors that are already encoded in the genome without DNA rearrangement, and the response is not specifically enhanced upon repeat exposure. Cells of the innate immune system respond to ligands that are often specific to pathogen-associated components such as peptidoglycan or double-stranded RNA (16, 17) . In the mucosal immune system, vaccination is intended to trigger an adaptive immune response that expands to the point at which a subsequent challenge by the target microbe is sufficiently robust to provide protection.
Innate immunity is critical for orchestrating the adaptive immune response through the activation of antigen-presenting cells (APCs) or induction of increased M cell activity. Initial systemic immune responses are governed by the innate immune system, which produces proinflammatory responses (via chemokines and cytokines) to the initial insult of infectious agents. Indeed, this initial rapid proinflammatory response by the innate immune system is considered to be the critical trigger provided by traditional immunological adjuvants. Thus, many vaccine formulation strategies include innate immune triggers to provide this adjuvant signal (18) (19) (20) . Innate immune triggers can fall into several categories, including Toll-like receptors (TLRs) (17) and non-Toll-like receptors (NLRs) (21) . These receptors are genomically encoded and recognize pathogen-associated molecular patterns (PAMPs) such as bacterial cell wall components (e.g., peptidoglycan, lipoteichoic acid) and uncommon forms of nucleic acids (e.g., double-stranded RNA, high-CpG-content DNA). Endogenous ligands produced by cell stress can also trigger innate immune signaling pathways. As noted above, these triggers are involved not only in the rapid production of inflammatory cytokines but also in the activation of APCs that trigger T cell responses. In the context of mucosal vaccine design, the aim is to induce an adequate innate immune response for initiating adaptive immunity without causing excess inflammation, tissue damage, or other sequelae. Although the intended cellular targets of adjuvant innate immune triggers are APCs, additional cells also express innate immune receptors such as mucosal epithelial cells (e.g., TLR2, TLR5, NOD2), which can also be triggered to produce inflammatory cytokines (22) . Thus, mucosal vaccine formulations need to consider potential off-target effects. Interestingly, many vaccine formulations, especially those using synthetic polymers, have the potential to be engineered to activate innate immune signaling pathways by incorporating structures that mimic microbial PAMPs. However, only a few studies have examined the utility of these materials for mucosal vaccination strategies. As mucosal vaccine development advances, we expect that the most efficient formulations will both aid in the delivery of vaccine antigens and promote innate immune stimulation.
Some innate immune triggers also play a direct role in triggering components of the adaptive immune response, and this triggering can be especially useful in mucosal vaccination. For example, the lipopolysaccharides of gram-negative bacteria can directly activate B lymphocytes and contribute to the stimulation of T cell-independent antibody production. As discussed above, a hallmark of mucosal immune response is the production of high levels of sIgA, which is thought to derive in large part from T cell-independent B cell responses, especially responses to polymeric antigens such as bacterial polysaccharides (23, 24) .
The adaptive cellular and antibody immune responses mediated by T and B lymphocytes appear to have rather different relative importance in mucosal tissues as compared with peripheral www.annualreviews.org • Mucosal Vaccine Design and Deliverytissues, so these differences should influence mucosal vaccination strategies. Whereas both CD4 + and CD8 + T cell subsets can have prominent cellular effector functions in peripheral tissues, T cells in the intestine may be dominated by cells with no pathogen-specific receptors (25, 26) . Indeed, many of these cells may carry only self-reactive receptors, and their persistence may depend on this self-antigen-driven selection. Moreover, antigen-reactive T cells activated at distant sites may preferentially migrate to the intestine where they persist, possibly as a local reservoir of memory cells (27) . There are higher proportions of B cells to T cells in organized mucosal lymphoid tissues compared with the proportions found in peripheral lymphoid tissues, and this seems to reflect their relative activity. Thus, in contrast to B cell responses in peripheral tissues, B cell responses in the intestine are more dependent on active contributions from a contingent of T cell-independent B-1 cells, which are responsive to polymeric antigens such as bacterial capsular polysaccharides and polymerized flagellin (28) . These cells are produced by early fetal liver stem cells as well as by a self-renewing population in the peritoneum, and their effector functions are critical in the early neonatal maturation of the immune system when T cell immunity is still developing. A T cell-dependent response is also important in the organized lymphoid tissues, where CD4 + T cells provide cytokines to help in the differentiation of activated B cells toward production of IgA antibodies. Thus, mucosal vaccination might benefit from targeting both T cell-independent and T cell-dependent B cell responses in the lymphoid tissues.
Correlates of Immune Protection Against Mucosal Pathogens
Identifying the immune responses that elicit mucosal protection will aid the rational design of effective mucosal vaccines and adjuvants. However, the lack of reliable and sensitive techniques for evaluating mucosal immunity has limited the measurement of correlates of mucosal protection and has hindered the development of mucosal vaccines. The correlate of protection for most existing licensed vaccines is the induction of antibodies that function in opsonophagocytosis or neutralization (29, 30) . A main goal for vaccines in humans is to inhibit mucosal replication of viral (influenza, rotavirus, polio) and bacterial (pertussis, typhoid) pathogens through locally secreted IgA or transcytosed IgG present on mucosal surfaces (29) . Mucosal antibodies present at the time of exposure to the pathogen have correlated with protection against local colonization and eventual systemic infection, as well as protection from pathologies of the mucosa associated with pathogen invasion. However, the titers of antibodies at mucosal surfaces that correlate with protection have been difficult to quantify statistically owing to large variations that result from sample collection and dilution. As a result, with the exception of studies testing protection offered by known quantities of antibodies topically administered directly to the mucosa (31), only estimates are available for actual antibody concentrations induced by vaccination at mucosal surfaces; therefore, serum antibody levels remain the best correlate of protection (29) .
The functional roles of IgG antibodies-which include opsonophagocytosis, neutralization, complement fixation, inhibition of epithelial transcytosis or cell-cell transmission, and antibodydependent cellular cytotoxicity-are also critical for defining the humoral correlates of mucosal protection. However, assays for antibodies are often based solely on antigen binding, which alone is not indicative of function and does not necessarily correlate with protection. For example, the meningococcal unconjugated polysaccharide vaccine given in young children leads to a significant ELISA-detectable antibody binding response but provides poor protection (32) . In this case, the level of bacterial antibody gradually increases with age, and serum titers of ≥1/8 are considered protective for all serogroups (32, 33) . It is unlikely that the relationship between levels of binding antibodies, measured conveniently and rapidly by ELISA, and levels of functional antibodies can be easily predicted a priori.
Although serum IgG levels can provide a reasonable surrogate marker of protective immunity, they cannot measure the role of sIgA. Studies on IgA-deficient mice show that transudation of serum IgG can indeed be sufficient to provide protection against infection at mucosal surfaces, but the unique effector properties of sIgA may provide additional benefits not tested. IgA, although protective at mucosal surfaces, does not fix complement or activate local inflammatory responses as does IgG. Serum levels of IgA also do not adequately represent levels of sIgA in specific local mucosal tissues. Thus, although humoral correlates of mucosal protection can clearly benefit from more sophisticated assessments of functional assays in the context of protection from mucosal pathogens, additional assays will need to be developed to focus on the specific local protective effects of IgA in mucosal sites.
Whereas antibody responses are the most direct measure of protective immunity, cellular immunity at mucosal surfaces is critical in both regulating immunity and providing direct effector responses. To date, the paucity of information on mucosal T cell quantity, quality, and duration in relationship to systemic T cell responses following infection or vaccination has significantly hindered the design of mucosal vaccines. There are several examples whereby T cells constitute the critical immunological correlate of protection whose function goes beyond simply helping B cells produce antibody. For example, the live-attenuated strain of Mycobacterium bovis bacillus Calmette-Guérin is the only vaccine available against M. tuberculosis, and cellular immunity is thought to be the primary function for protection (34, 35) . Although antibodies may play a role in enhancing macrophage uptake of mycobacteria, it is argued that this effector function does not significantly contribute to protection (36) . In the case of live-attenuated influenza vaccine (e.g., FluMist R ), cytotoxic CD8 + T cell responses are thought to contribute significantly to cross-reactive protection against influenza variant strains (37). In another example, rapid Th17 responses to Salmonella infection have been considered either to assist the bacterial colonization of the intestine or to provide a barrier to invasion across the intestinal epithelium (38, 39) . Thus, mucosal vaccination strategies to specifically modify T cell responses at mucosal surfaces can have a significant impact on host defense.
MUCOSAL BARRIERS TO VACCINE DESIGN
Current methods of vaccination target the systemic immune system and elicit only a weak mucosal immune response. Mucosal responses are most efficiently potentiated when the vaccine is delivered directly onto mucosal sites. However, direct mucosal immunization has proven difficult. One challenge of mucosal immunization is that mucosal vaccines tend to become diluted in mucosal fluids, and bulk flow may limit effective deposition onto the epithelium of the mucosal system (40) . Additionally, mucosal vaccines have the propensity to become stuck within the mucus gel and are subsequently degraded by proteases. Recent literature suggests that mucosal vaccines might be more efficient if they were designed to mimic physicochemical properties of opportunistic pathogens, specifically charge and size (40, 41) .
A variety of strategies exist for the delivery and presentation of immunomodulatory molecules to the host immune system. Of these strategies, those that will be effective for mucosal immunization will require (a) overcoming physiological barriers at mucosal routes, (b) targeting of mucosal APCs for appropriate processing of antigens that lead to specific T and B cell activation, and (c) controlling the kinetics of antigen and adjuvant presentation in order to promote long-lived, protective adaptive immune memory responses. The challenge for mucosal vaccine design is to increase immunogenicity without compromising safety. To this end, one approach is to develop vaccines based on infectious viral or bacterial pathogens that have been rendered safe by attenuation or inactivation. Another approach is to employ subunit vaccines using recombinant viral or bacterial proteins that can be rendered sufficiently immunogenic without leading to reactogenicity. A third and promising approach for mucosal vaccine development is based on synthetic particulate delivery systems designed to mimic immunogenic properties of natural pathogens. These approaches are discussed in detail below with special attention given to their application for mucosal immunization.
Mucoadhesion and Mucus Penetration
Mucus is a highly viscous and heterogeneous microenvironment that presents a significant barrier not only to pathogen entry but also to mucosal vaccine delivery. To be effective, mucosal vaccines must prevent inactivation of the antigen or adjuvant by the harsh mucosal environment and deliver the vaccine across mucosal barriers to target mucosal tissues and cells. Both the viscosity and pore size of mucus can impede significantly the diffusivity of agents delivered to mucosal surfaces. The shear-dependent bulk viscosity of mucus is typically 100-10,000 times greater than the viscosity of water (42) . The pore size of mucus was originally estimated to be between 20 nm and 200 nm on the basis of electron microscopy images of cervicovaginal mucus (CVM), which has a composition similar to that of mucus found in the lung and nasal carriage (43) . However, recent measurements using multiple-particle tracking have identified larger CVM pores of 50-1,800 nm. This pore size is significantly larger than human viruses, yet human immunodeficiency virus (HIV) and herpes simplex virus (HSV) still show significantly reduced diffusivity in human CVM (44, 45) . Hydrophobic and electrostatic interactions between these viruses and the mucin fibers are thought to aggregate the mucus microstructure and hinder diffusion by trapping the viruses.
Studies on the mucosal transport of synthetic carriers with controlled size and surface chemistry have provided useful insight into the design criteria of vaccines meant for mucosal delivery. Hydrophilic and net-neutral surface chemistries are thought to promote mucus penetration (diffusivity) (42, 46) . In contrast, mucoadhesion is enhanced by highly hydrophobic or positively charged surfaces that may interact with the negatively charged mucus layer and impede diffusion. Striking an appropriate balance between mucus penetration and mucoadhesion depends strongly on the thickness of the mucus layer and its residence time on the mucosal tissue. For example, the thickness of human CVM (∼200 μm) and its clearance time (6-17 h) may be conducive for nanocarriers with a range of diffusivities and adhesive properties, whereas faster clearance times may require enhanced mucus penetration. Surface modification of drug delivery vehicles has proven to be a beneficial tool to increase both mucoadhesion and mucus penetration. Several natural materials such as chitosan (formed by the deacetylation of chitin), alginate, and derivatives of cellulose show strong mucoadhesive properties owing to the presence of numerous hydrogen-bond-forming groups (47). Rajapaksa et al. (41) showed that coating the surface of poly (lactic-coglycolic) acid (PLGA) nanoparticles with poloxamer 188, which acts as a surfactant, helped increase the diffusivity and uptake of these particles by mucosal surfaces. Polyethylene glycol (PEG) is a bioinert synthetic polymer that can function to enhance mucus penetration or mucoadhesion on the basis of its molecular weight. Nanocarriers grafted with long PEG chains (≥10 kDa) are more mucoadhesive, whereas those with shorter PEG chains (≤2 kDa) have greater mucosal diffusivity (42) . High-molecular-weight PEG is thought to entangle with the mucus gel, causing interpenetration and secondary interactions between the PEG and the mucus glycoproteins to promote adhesion (47) . The concepts of mucus penetration and mucoadhesion will have a significant role in achieving effective transport of vaccines administered mucosally.
Targeting Epithelium, Microfold Cells, or Dendritic Cells
Encapsulation of antigens in polymer-based particles can be a vital tool for delivery of vaccines to mucosal sites. However, without proper targeting, these carriers may not be successfully internalized, processed, and presented in a way to direct immunological function. Because mucosal DCs are among the first cells to encounter pathogens at the site of mucosal entry, numerous ligands have been examined to target these specialized APCs. Targeting APCs, specifically DCs, was first pioneered by the research groups of Steinman and Nussenzweig (48) (49) (50) , who were the first to identify receptors expressed specifically by these cells. The C-type lectin receptors are a family of calcium-dependent lectins expressed on the surface of DCs. Strategies to target these receptors have used natural ligands for the receptor, such as the sugars mannose and mannan, or antibodies directed against the receptor. Most examples of DC-targeting strategies employ the well-characterized DC receptor CD205 (also known as DEC205), DC-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN), or the mannose receptor. Langerin is a receptor on specialized intraepithelial DCs named Langerhans cells found in type II mucosae. The expression patterns of these receptors differ not only among immature versus mature DCs but also among the different mucosal DC subtypes present in type I and type II mucosae (4, 51) . The intracellular routing of the receptor and hence the antigen presentation pathways are also characteristics of the targeted receptor. All of these factors must be considered for successful design of DC-based mucosal vaccines. Although targeting APCs is not unique to mucosal vaccination strategies, it could help potentiate stronger immune responses to antigens that are delivered mucosally.
Mucosal epithelial cells represent another opportunity for targeting mucosal vaccines. The neonatal Fc receptor, FcRn, is present on some type I mucosal epithelia and is involved in transepithelial transport of IgG (52) . Galactosyl ceramide is an enriched glycosphingolipid found in the apical membranes of mucosal epithelial cells of the endocervical, rectal, and gastrointestinal mucosae (53) . Another method that has been employed to encourage adhesion between mucosal epithelium and the vaccine delivery vehicle is to use high-affinity targeting ligands against M cells. However, few M cell receptors can be targeted for vaccine delivery. Indeed, some receptors have been identified only for the mouse and not for human M cells, limiting their usefulness in clinical settings. Clostridium perfringens enterotoxin (CPE) has been identified as a high-affinity ligand for M cells. Specifically, CPE binds Claudin-4 expressed on the apical surface of mucosal M cells. Rajapaksa et al. (54) found that the use of the C-terminal loop of CPE (residues 184-319) linked to recombinant protein and encapsulated into the matrix of PLGA nanoparticles could increase selective uptake of the nanoparticles by M cells.
M cells tend to exhibit unique glycosylation patterns, and lectins have been studied in animal models to use for targeting mucosal M cells. Ulex europaeus agglutinin 1 (UEA-1), a lectin that specifically binds α-1-fucose, is the most widely investigated M cell-targeting lectin (55) . In fact, UEA-1 selectively binds to M cells in Peyer's patches of the small intestine in mouse models. Many studies have focused on conjugating UEA-1 lectin to polymerized nanoparticles to target the apical surface of mouse M cells (55, 56) . Foster et al. (57) tested whether attachment of UEA-1 to commercially available latex microspheres could increase their affinity to mouse Peyer's patches. Results indicated that UEA-1-coated microspheres increased adherence to M cells compared with control microspheres. Recently, Manocha et al. (58) reported the use of PLGA nanoparticles conjugated with UEA-1 for M cell targeting. In this study, mice immunized with encapsulated HIV peptides in PLGA-UEA-1 carriers showed a two-to fourfold increase in antibody titers. UEA-1 has proven to be a vital tool in studying M cell-targeted delivery in mouse models. Unfortunately, UEA-1 cannot be used to target human M cells owing to the
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fact that human M cells do not express the necessary α-1-fucose moiety on their apical surfaces (55).
Recapitulating the Kinetics of Infection
Timing the presentation of antigens and adjuvants to mimic the kinetics of pathogen infection may be critical to the design of protective mucosal vaccines. The key for induction and maintenance of protective viral immunity is thought to be associated with the kinetics of initial rapid viral replication followed by virus elimination to low levels (59, 60) . Attempts to mimic the kinetics of infection have shown that coordinating the time of adjuvant and antigen delivery can have a profound effect on the resulting T and B cell response (61) . For example, enhanced CD8 + T cell responses have been observed when antigens are coadministered with adjuvants such as TLR ligands (62), α-galactosylceramide (63), or CD40-specific antibodies (64) . In contrast, delivery of adjuvants too early or too late after antigen delivery can impair antigen cross-presentation (65, 66) . The choice to deliver antigens separately or in combination, either mixed or physically conjugated, with the adjuvant also affects their colocalization in phagosomes and efficiency for presentation by APCs. Blander & Medzhitov (67) showed that DC maturation and major histocompatibility complex (MHC) class II presentation occur only when TLR ligands and antigens colocalize within the same phagosome. A recent study by Kasturi et al. (68) observed that enhanced antibody titers and germinal center formation were induced when antigens and adjuvants were delivered separately in biodegradable nanoparticles. Several studies have shown that prolonged antigen exposure in mice can result in costimulation-independent T cell responses and long-lived T cell memory. Cranage et al. (69) demonstrated recently that repeated vaginal administration of HIV-1 gp140 without an adjuvant can induce serum and mucosal antibody responses. Although vaccination schedules and coordination of the delivery of antigens and adjuvants have been well studied for nonmucosal routes of immunization, we still know little about how these parameters will translate into effective mucosal vaccines.
Commensal Microbes and Mucosal Immunity
Mucosal immunization is intended to provide a protective immune response against pathogenic microbes in the lumen, but mucosal tissues are also abundantly colonized by nonpathogenic microbes referred to as commensal microbes. Although they are often considered symbiotic, commensal microbes can also cause disease if they appear in the wrong part of the body or if they overgrow the mucosal tissue. Thus, providing a clear definition of what constitutes a commensal is difficult, and, indeed, the mucosal immune system often generates immune responses such as sIgA antibodies against many bacteria that would otherwise be considered commensal (70) . Commensals also can have a significant influence on mucosal immune regulation and can be a factor in the effectiveness of mucosal vaccination.
Although the study of mucosal microbial communities is still in its early stages, a few instances of the influence of commensal microbe on mucosal immunity have been identified. For example, the intestinal epithelium recognition of microbes through TLR2 signaling is known to be critical to epithelial integrity and homeostasis, as it regulates tight junction development (71, 72) . Direct effects on immune regulation have also been described. In one case, a polysaccharide produced by the commensal Bacteroides fragilis directly regulated development of regulatory T cells (73, 74) . More generally, the manipulation of intestinal microbes in a highly restricted flora altered the relationship among lymphocyte populations in the intestine, with CD8 + T cell-mediated reductions in numerous regulatory cell types (75, 76) . Thus, the colonization of mucosal sites by commensals and their balance with other potentially pathogenic microbes can play a large role in determining the effectiveness of mucosal vaccines. This is an especially important factor in the developing world, where additional influences of intestinal pathogenic bacteria and parasites on T cell regulation can override the intended effects of the vaccines and adjuvants.
Immunity Versus Tolerance
Mucosal vaccine formulations have the practical benefit of needle-free administration, but other factors add uncertainty to the development of dosing and formulation strategies. For example, whereas many pharmacologic agents require strict control over dose delivery with specific targets for plasma levels, an "ideal" target-delivered dose of vaccine is not easily identified. An effective immune response may also require one or more booster doses to amplify the initial primed response and solidify memory immune responses. Thus, the dosing is complicated by the need to establish the dosing and timing of booster shots to induce sufficient protective immunity in the largest proportion of recipients. In the case of mucosal delivery, effective delivery of vaccine to immune cells is complicated by the variability in the uptake mucosal environment, by superimposed immunological effects of ongoing infection or inflammation, and by variable requirements for booster doses.
Although a goal of mucosal administration of vaccine is to induce protective immunity, a well-known phenomenon termed oral tolerance or mucosal tolerance is associated with mucosal administration of antigen (77, 78) . Indeed, some targeted vaccination strategies induce immunological tolerance instead of immunity; this occurs mainly with protocols in which an immunological adjuvant is not provided. This phenomenon applies to both T and B cell responses, although in some cases a split tolerance can exist, whereby, for example, a T cell response coexists with B cell tolerance. Classically, immunological tolerance induction, mucosal or otherwise, depends on the dose and timing of antigen delivery. Low-zone tolerance is induced by low doses over a long period of time, and high-zone tolerance is induced by a high dose that overwhelms the immune system. The mechanisms invoked have variably included central or peripheral deletion of reactive cells and activation of regulatory T cells, but in all cases they depend on active recognition of antigen by immune cells. Mucosal vaccine delivery formulations need to take these possibilities into account. Low-dose extended release delivery may be useful for pharmacologic agents, but for vaccine antigens the slow release could lose the benefit of adjuvant activity and induce tolerance. By contrast, rapid delivery of a high antigen dose could have the potential to induce high-zone tolerance. Thus, in consideration of the various controlled-release designs described below, optimal antigen release kinetics must be sought.
Tolerance induction (also known as immune deviation) might, in some cases, be an intentional goal, as in the case of autoimmune disease or allergen immunotherapy. Sublingual administration of allergens is being explored (79), although delivery formulations are still simple. In clinical settings, one theoretical complication is concurrent infection, and associated innate immune activation could have the potential to provide adjuvant activity. However, allergen immunotherapy is generally used in the setting of existing immunity (allergy), so abrogation of intended tolerance induction is less likely. It is not known if preventative tolerance induction is more likely to risk immune induction rather than tolerance if administered in the presence of mucosal infection.
DESIGN STRATEGIES FOR MUCOSAL VACCINES
The promise of mucosal vaccines is that they can be designed to recapitulate the earliest cellular interactions with local APCs and mucosal follicles to generate local immune responses, conferring 
mucosal immune responses. Ideally, mucosal vaccines target inductive sites in mucosal tissue and promote interaction with local cells of interest. The architecture, size, and surface chemistry of particulate carrier systems can also be manipulated to maximize interactions with immune cell targets ( Table 1) . The following discussion focuses on the design principles that are useful in developing novel mucosal vaccines. In particular, we highlight several delivery systems that can be used to target vaccines (both antigen and adjuvant) to appropriate cells of the mucosal immune system and also used to ensure proper and optimal immune stimulation. 
Live-Attenuated or Inactivated Vaccines
Vaccines based on live-attenuated viruses or microbes that have been inactivated by heat or chemicals comprise the majority of licensed vaccines used for the prevention of infectious disease (80) . To date, these are the only vaccines approved for mucosal delivery and the only ones for which efficacy is correlated with effector mucosal immune responses (80, 81) . The oral polio vaccine is a live-attenuated vaccine that produces serum antibodies as well as local sIgA in the intestinal mucosa. The mucosal sIgA confers protection from poliovirus entry and multiplication. Several live-attenuated vaccines administered via the mucosal (oral) route are licensed for enteric infections such cholera, typhoid, and rotavirus. The success of live-attenuated and inactivated vaccines is attributed to the presentation of multiple immunogens and adjuvanting second signals that combine to elicit strong antibody and cellular responses and long-term memory. However, not all viruses can be attenuated, and the risk of reversion can compromise safety, especially for viruses with ill-defined attenuation. Although inactivation of viruses and bacteria is a more generalizable approach and although these vaccines are much safer, inactivated vaccines can exhibit loss of antigens or PAMPs. This loss results in rapid waning of protective immunity and causes the inactivated vaccines to be less effective than live-attenuated vaccines. Thus, a goal for synthetic or engineered mucosal vaccines is to identify the immunostimulatory factors of attenuated or inactivated microbes. These factors could include antigen persistence at mucosal sites, induction of tissue inflammation or innate immune stimulation, or other cellular responses associated with tissue infection by pathogenic microbes.
Subunit and Conjugate Vaccines
Vaccines based on pathogen-specific proteins or based on polysaccharides conjugated to proteins or peptides are the second largest category of licensed prophylactic vaccines. We include in this category the toxoid vaccines, which are typically isolated and inactivated bacterial toxins designed to elicit immunity to the toxic compounds (rather than to the live microbe) responsible for the disease. Examples of toxoid vaccines are the diphtheria toxin vaccine and tetanus toxin vaccine that (82), a subunit vaccine consisting of the HSV-2 envelope glycoprotein fused to the IgG Fc fragment was delivered intranasally; it elicited systemic as well as mucosal B and T cell responses and conferred protection from intravaginal challenge with HSV-2. Furthermore, repeated intravaginal immunization of recombinant HIV-1 envelope protein (gp140), without the use of a mucosal adjuvant, induces systemic and mucosal neutralizing IgG antibodies (69) . Another exciting area in subunit vaccines has emerged recently with the use of proteins of defined structures as scaffolds for the presentation of immunogenic epitopes (83) (84) (85) . Epitope scaffold vaccines have been rationally designed for HIV-1 envelope protein gp41 epitopes known to elicit broadly neutralizing antibodies (2F5 and 4E10) (84, 85) . Some epitope scaffold designs had 1000-fold-higher binding affinity for their neutralizing antibody and firmly established that epitopes grafted onto the backbones of proteins can potentially serve as stable immunogens for antibody generation (84) .
Mucosal immunization with subunit vaccines has unique challenges associated with not only the immunogen but also the route of antigen delivery. Mucus does not appear to hinder the diffusion of soluble proteins, and transport of large protein antigens should be possible (86) . However, mucosal immunization with protein antigens is limited by the need to protect the protein antigens from degradation by mucosal proteases or commensal microflora. In addition, subunit vaccines are typically poorly immunogenic and require the use of adjuvants to be effective. Few adjuvants are approved for human use, and safe and effective mucosal adjuvants are particularly lacking. Vehicles engineered to protect and deliver antigens with appropriate mucosal adjuvants to stimulate the innate immune system should enhance the efficacy of subunit vaccines. In the next sections, we discuss the use of particulate delivery systems for mucosal vaccines.
Virus-Like Particles and Virosomes
Virus-like particles (VLPs) and virosomes constitute a category of subunit vaccines wherein the immunogens are derived from viral components that self-assemble into higher-order threedimensional architectures that preserve the antigenic structure of virus immunogens. VLPs are formed from the self-assembly of one or more viral capsid or envelope proteins that are expressed recombinantly in mammalian or insect cells. The hepatitis B vaccine was the first commercially viable VLP-based vaccine. It is produced from the self-assembly of the hepatitis B surface antigen (HBsAg) expressed recombinantly in yeast cells. The human papillomavirus (HPV) vaccine has been the only other VLP since to be licensed for human use. The quadrivalent HPV vaccine from Merck & Co. (Gardasil R ) is composed of the L1 capsid proteins of HPV-6, -11, -16, and -18 types that are expressed recombinantly in yeast and self-assembled into VLPs (87) . The mechanism of protection afforded by the VLP vaccines for HPV is not fully understood, and no immune correlates have been linked definitely to protection. Protection is posited to be due to serum-neutralizing IgG that transudes across the cervical epithelium in sufficient concentration to bind HPV virions and prevent infection (88) (89) (90) (91) . Like subunit vaccines, currently licensed VLP vaccines require coadministration with adjuvants to be effective.
Virosomes can be regarded as a special category of liposome vaccine delivery systems (see below) whereby viral membrane proteins are integrated into unilamellar vesicles composed of viral and other natural or synthetic lipids (92) . The most advanced virosomal systems are based on lipids (derived from viral, egg, or synthetic lipids) and membrane proteins of influenza virus; they are referred to as immunopotentiating reconstituted influenza virosomes (IRIVs). A defining feature of IRIVs is the presence of the influenza-derived proteins hemagglutinin and neuraminidase, which distinguish these virosomes from all other lipid-based particulates such as liposomes. Epaxal R (Crucell, Netherlands) is a virosome vaccine for hepatitis A that is made by adsorption of formalininactivated hepatitis A virus onto IRIVs (93) . Inflexal R V (Crucell, Netherlands) is a trivalent influenza vaccine based on a mixture of three monovalent virosomes reconstituted from different influenza virus strains (94, 95) . Preexisting immunity against influenza is important for the adjuvant activity of IRIVs. In a recent novel mucosal vaccine application of virosomes, Bomsel et al. (96) evaluated the protective efficacy of IRIVs grafted with HIV-1 gp41 subunit antigens. They showed that their HIV-1 gp41 subunit IRIV administered in two doses intramuscularly followed by two doses intranasally fully protected against vaginal simian-HIV challenge, whereas four intramuscular doses resulted in only 50% protection (96, 97) . Protected animals had antigenspecific IgA antibodies that blocked HIV-1 transcytosis and IgG antibodies with neutralizing or antibody-dependent cellular cytotoxicity activities. Surprisingly, these animals lacked serumneutralizing antibodies, suggesting that vaccine-induced mucosal antibodies may be critical for protective immunity against HIV-1 (97).
Despite a limited number of VLP and virosome vaccines approved for human use, they represent an exciting platform for the development of novel mucosal vaccine strategies. Both VLPs and virosomes are sufficiently small, and the composition of their surface chemistry can be designed to minimize hydrophobic and electrostatic adhesive interactions with mucus. VLPs have the flexibility of being produced using different expression systems. They can also be engineered for recombinant expression of multiple antigenic epitopes and for incorporation of costimulatory and immunoregulatory proteins. However, VLP technology can be limited by difficulties of scale-up, the need for purification from the expression systems, and the requirement for adjuvants. Only virosomes have been used effectively without additional adjuvants (98), so they may be attractive as mucosal vaccines. Although both VLPs and virosomes have great potential as vaccine carriers, they are harder to formulate and are less reproducible compared with entirely synthetic polymer nanoparticles.
Nonviral, Polymer-Based Carrier Systems
Polymer-based micro-and nanocarrier systems are a growing technological platform for the design of novel mucosal vaccines ( Table 1) . In recent years, we have observed innovative approaches to engineering these carriers to overcome mucosal barriers so that vaccines and adjuvants can be delivered to the oral, nasal, and anogenital mucosae. The carriers can be made of a variety of materials-such as natural or synthetic polymers, lipids, proteins, or inorganic materialsto form particles and capsules of controlled size and architecture. Nanocapsules constitute a reservoir delivery system wherein the vaccine can be enclosed within an aqueous or oil-based core surrounded by a solid or semisolid material shell. In contrast, nanoparticles are solid particles wherein the immunogens are dispersed within the polymer matrix or adsorbed to the particle surface. These carrier technologies can be designed to deliver low-molecular-weight compounds as well as biologics (peptides, proteins, nucleic acids) that become bioavailable upon particle degradation, erosion, swelling, or diffusion from the polymer matrix. Biomaterials are also selected for their biocompatibility and their ability to be engineered for tissue and cell targeting. Therefore, nonviral carrier systems have the potential to be uniquely designed to control the spatiotemporal delivery of vaccine antigens and adjuvants to mucosal inductive sites. In the next sections, we describe the materials and features of different carrier types and provide recent examples of their application for mucosal vaccines.
3.4.1. Nanocapsules. Emulsions and liposomes are two types of nonpolymeric carrier systems that are marketed for human use and have shown promise as mucosal vaccines. Nanoemulsion technologies are liquid suspensions that exhibit long-term colloidal stability and have been used to encapsulate and deliver vaccines directly onto mucosal surfaces. Nanoemulsion droplets are formed by the dispersion of two immiscible liquids. They range in size from 20 nm to 200 nm, which is similar to the size of opportunistic pathogens, and are readily taken up by mucosal M cells and subsequently presented to APCs (99) . Table 1 presents an overview of the major classes of nanoemulsions. Briefly, water-in-oil emulsions incorporate and deliver hydrophilic drugs much more efficiently than do oil-in-water emulsions, which are used to incorporate and deliver hydrophobic drugs (100). Single-nanoemulsion technology has been successfully employed in the generation of a hepatitis B vaccine. Makidon et al. (101) showed that recombinant HBsAg could be emulsified into uniform droplets and delivered to mucosal effector sites intranasally. The HBsAgnanoemulsion system generated a strong immune response, producing high titers of both IgA and IgG; this strong response indicates the usefulness of nanoemulsion for NALT mucosal immunization. Unfortunately, single-nanoemulsion methods have poor controlled-release profiles (80, 102) and may not be able to withstand degradation within mucosal sites other than NALT (100). Hanson et al. (103) introduced the concept of a double-emulsion method with good controlledrelease profiles. Double-emulsion technology has proven useful for delivering vaccines to mucosal surfaces before they are degraded. Additionally, double emulsions are more stable and are able to encapsulate antigens without deleterious effects to the antigen during the emulsification process (80, 104) . Nanoemulsion technology has provided a novel delivery method for immunizing the mucosal immune system.
Liposomes are nonpolymeric carriers that have been used extensively for drug delivery and show great promise as vaccine carriers for mucosal immunization. They can be composed of a variety of phospholipid molecules that are based on the structure of natural biological membrane lipids. Liposomes are poorly water soluble and self-assemble into a phospholipid bilayer that can form a multilamellar or unilamellar vesicle that encloses an aqueous compartment (105) . The hydrophobic bilayer and the aqueous core of the liposome are suitable for delivering lipophilic or hydrophilic cargo, respectively (106) . Methods to prepare liposomes can generate small (<50-nm) or giant (>1-μm) unilamellar vesicles (107, 108) . In addition, selection of lipids can be tailored for specific function. For example, cationic lipids can be tailored for complexation and efficient delivery of nucleic acids, and pH-titratable lipids can be tailored for pH-triggered release of agents (106, 109, 110) . Furthermore, liposomes are readily surface modified with ligands for tissue and cell targeting, steric stabilization, mucoadhesion, and mucus penetration. Although the lipid matrix has been considered generally inert, certain lipid constituents may induce inflammation, and care must be taken to select appropriate lipid compositions for mucosal delivery. The preparation of liposomes of different composition, size, and function makes them versatile carriers for mucosal vaccines. Many groups using liposomes for mucosal immunization against invading pathogens and viral infection have shown promising results; we refer the reader to illustrative examples provided in a recent review by Romero & Morilla (111) . In general, liposome-based mucosal vaccines have been used primarily for oral or intranasal immunization. Rosada et al. (112) showed that a single intranasal immunization with cationic liposomes delivering a DNA encoding for a tuberculosis heat-shock protein could protect against challenge with the bacterium by eliciting strong cellular immune responses. Liposomes have also been fabricated using immunomodulatory lipids such as polycationic sphingolipids or cationic cholesterol derivatives that can exhibit adjuvanting activity upon mucosal delivery (113, 114) . Recently, an interbilayer, cross-linked multilamellar vesicle was used to codeliver antigen and adjuvant (115) . These stabilized liposome vaccines enhanced humoral and cellular immune responses 10-1,000-fold compared with the responses caused by soluble antigen alone or non-cross-linked multilamellar vesicles. These novel lipid systems were used as subcutaneous vaccines but may have interesting applications for mucosal vaccines. Despite the large number of preclinical studies testing the efficacy of liposomes as mucosal vaccines, no products are approved for clinical use. Future advances will enhance our ability to better understand how the lipid matrix can be engineered to interact more effectively with the mucosal immune system.
Nanoparticles.
The versatility of polymeric particles for mucosal vaccine design arises from the availability of different polymers and methods for particle synthesis, which leads to specific types of nanoparticles such as micelles, dendrimers, and solid matrix nanoparticles composed of synthetic or natural polymers. Common polymer compositions of nanoparticles include biodegradable or bioeliminable synthetic polymers [e.g., polyesters, polyanhydrides, poly(amino acids)] and natural polymers (chitosan, alginate, albumin), copolymers, and polymer blends (116) . Both synthetic and natural polymer-based micro-and nanoparticle carrier systems are widely used in drug delivery applications and show the greatest versatility for designing effective mucosal vaccines (116) . A primary goal of nanoparticle mucosal vaccine design is to protect the antigen from degradation upon mucosal delivery, penetrate mucosal barriers, and control the release of the antigen and costimulatory or immunomodulatory agents in specific cells and intracellular compartments. Nanoparticle size, composition (surface chemistry and polymer architecture), and ability to control the presentation of antigen and PAMPs have important roles in immune activation.
Size plays a critical role in the amount of antigen that can be delivered as well as the manner in which the antigen is internalized and processed by the mucosal immune system. The selection of polymers and fabrication method can generate nanoparticles with a wide range of sizes and geometries. Polymeric micelles and dendrimers can be synthesized in the ultrasmall (<25 nm) size range. Polymeric micelles are composed of amphiphilic block copolymers that have hydrophilic and hydrophobic segments that typically exhibit large solubility differences. The solubility difference drives the assembly of nanoparticles with unique core-shell architectures that are useful for delivering agents encapsulated within the core or attached to the polymer shell (117) . Although polymer micelles can achieve small sizes, they are prone to dissociate upon dilution, which can result in unintended release of their cargo. Synthesis of new block copolymers has led to the development of controlled-release micellar systems. Like micelles, dendrimers can be used for noncovalent encapsulation of vaccines or formation of covalent dendrimer-vaccine conjugates (118) . Dendrimers offer greater stability compared with polymeric micelles owing to the covalent bonds that form the branched polymer network.
In contrast to polymeric micelles and dendrimers, biodegradable systems synthesized from natural or synthetic polymers typically range in size from 100 nm to >1 μm. Internalization of polymer nanoparticles at various mucosal sites has been reported to be highly size dependent. As mentioned in Section 2.1, the mesh-pore spacing of mucus is 50-1800 nm (45) , which should accommodate the transport of many polymeric nanoparticle carriers as long as hydrophobic and electrostatic mucoadhesive forces can be minimized. Many studies have delineated the optimal size needed to increase nanoparticle uptake by cells of the mucosal system. Shakweh et al. (119) found that rhodamine 6G-labeled PLGA particles ranging in size from 0.3 to 1 μm were internalized by mucosal Peyer's patches, whereas larger-sized particles were not. Conversely, NALT nanoparticle uptake studies suggest the optimal size to be approximately 0.1 μm (54). The sizes of nanoparticle vaccines also greatly influence the kinetics of lymphatic drainage; specifically, nanoparticles <200 nm are readily transported by the draining lymph, but larger particles require cellular transport (120, 121) . Lymphatic drainage of vaccine carriers from mucosal tissue has yet to be fully examined.
In addition to size, the surface chemistry and polymer composition of nanoparticles can be specifically engineered to overcome transport barriers, interact with tissues and cells, and promote specific immunomodulatory function at mucosal sites. The hydrophobicity or hydrophilicity, as well as charge, of the nanoparticle surface can alter the microstructure of mucus and lead to mucoadhesion or mucus penetration. Hydrophobicity is also thought to be a damage-associated molecular pattern that causes innate immune activation (122) . The surface of nanoparticles can also be decorated with specific functional groups such as surface hydroxyls that bind C3b and activate complement (121) . In addition, surface conjugation of ligands may be useful for introducing highly organized and repetitive structures that mimic PAMPs. Jain (123) 
and CD8
+ T cells ex vivo more effectively than soluble protein antigen alone. A similar nanoparticle design used PLGA nanoparticles to codeliver CpG oligonucleotides and a recombinant envelope protein antigen from the West Nile virus, and it generated effective humoral responses (125) . The value of similar polymeric nanoparticle designs for mucosal vaccine delivery still needs to be validated.
Numerous polymeric nanoparticle designs have also used ligands to promote targeting and uptake by mucosal epithelia and APCs, as described above. Most of these DC-targeting approaches have been applied to mouse bone-marrow-derived DCs or subcutaneous DCs but not mucosal DCs. For example, nanoparticles consisting of a PLGA core were surface modified with a PEG lipid carrying a humanized antibody targeting DC-SIGN, and they targeted human DCs effectively (126). Bandyopadhyay et al. (127) showed that the density of DC-targeting ligands on the surface of nanoparticles may modulate the cytokine response and expression of scavenger receptors. For example, they demonstrated that increased surface density of anti-DEC205 correlated with higher cross-linking of its receptor and resulted in decreased expression of CD36. This is an important observation that may be valuable for the design of particulate systems for vaccine delivery. Polymer-based strategies also modulate intracellular trafficking to bias antigen presentation by MHC class I or MHC class II pathways. For example, stimuli-responsive polymers that are sensitive to changes in pH or redox potential have been used for intracellular targeting of antigens. Polymer nanoparticles based on propylacrylic acid and polycations have been used to promote endosomal escape of antigens into the cell cytosol for MHC class I presentation. The pH-sensitive acrylic acid or ketal-containing nanoparticles destabilize membranes in a pHdependent manner and take advantage of the acidification of endosomes (128, 129) . Polycations also function to destabilize membranes by a different mechanism that promotes osmotic swelling and ultimately bursting of endolysosomes owing to sequestration of protons by the biomaterial (130) . Redox-sensitive polymers have also been extensively explored to take advantage of the different redox potential in the endosome (reductive) versus the lysosomes (oxidative) (131) . These stimuli-responsive polymers will be a valuable component of synthetic mucosal vaccine delivery systems.
Particulate delivery systems based on synthetic or natural polymers that are biodegradable offer opportunities to control the timing of antigens and adjuvant presentation. Emulsification techniques are used commonly to fabricate nanoparticles. Nanoparticles can be formed from emulsions through a variety of techniques that induce polymer precipitation upon solvent removal by extraction, evaporation, diffusion, or de-salting (132) . Nanoparticles can also be fabricated by gelation of polymers dispersed in emulsion droplets (133) . This method is applicable only to polymers that exhibit gelling properties in response to temperature, pH, or addition of cross-linking agents. Dispersion of monomers within emulsion droplets can also give rise to nanoparticles by in situ polymerization. Particulate carriers fabricated using the copolymer PLGA represents one of the most widely utilized delivery platforms for vaccines. PLGA has an excellent controlled-release profile, excellent toxicological profiles, and US Food and Drug Administration approval (123). Woodrow et al. (124) showed that topical delivery of fluorescently labeled PLGA nanoparticles to the vaginal mucosa resulted in distribution and penetration of the particles throughout the local tissue. Cellular uptake and trafficking likely contributed to the observed tissue distribution. The surfaces of PLGA nanoparticles are easily modified to express tailored physiochemical properties that enhance particle diffusivity through the mucosa and transcytosis by mucosal M cells (41, 123, 134) . One of the most important attributes of PLGA is that vaccine antigens can be encapsulated into the matrix or on the surface of PLGA carriers (134) . Although most applications of PLGA nanoparticles have been in subcutaneous or intramuscular depot injections, many groups have turned their attention to studying PLGA nanoparticles as a possible delivery vehicle for mucosal immunization (135) . Efforts have been made in delineating the optimal conditions for increased uptake of PLGA microspheres across the mucosal barrier.
Mucosal adjuvants.
Vaccination through mucosal routes requires potent adjuvants to enhance immunogenicity. However, few mucosal adjuvants exhibit sufficient potency without being toxic or reactogenic, and still fewer are approved for human use ( Table 2 ). The only adjuvants clinically approved in the United States are aluminum salts and specific types of emulsions. An adjuvant combining aluminum salts with a TLR4 agonist (monophosphoryl lipid A, also known as MPL) was recently approved for use with injectable vaccines for hepatitis B and HPV (136) . The mechanism of action of adjuvants is poorly understood, and this poor understanding has hampered the development and rational design of new adjuvant compounds. Since the approval of aluminum salts as an adjuvant almost 80 years ago, its mechanism of action is still debated and widely controversial. We attempt to highlight approaches used in immunopotentiation of mucosal vaccines and discuss recent advances that may spur the development of novel mucosal adjuvants.
The immunopotentiating activity of adjuvants may be mediated by different mechanisms of action ( Table 2) . Adjuvants can enhance the immunogenicity of vaccine antigens by eliciting a proinflammatory environment that recruits and promotes the infiltration of phagocytic cellsparticularly APCs-to the site of injection. Adjuvants may also exert their immunopotentiating effects by enhancing antigen presentation, inducing cytokine expression, or by activating APCs. The combination of a vaccine antigen and a specific adjuvant is still mostly an empirical process, but several adjuvants that have been evaluated in clinical trial are known to induce specific effector adaptive immune responses. Of particular interest as mucosal adjuvants are toxin-based adjuvants [heat-labile enterotoxin (LT), cholera enterotoxin (CT)], immunostimulatory adjuvants (e.g., MPL, CpG, QS21), and particulate adjuvants [e.g., emulsions, immunostimulating complexes (ISCOM)]. The most potent mucosal adjuvants available are LT from E. coli and CT from V. cholerae, but they are too toxic for use in humans. Therefore, mutants of the native toxins have been generated by site-directed mutagenesis to reduce the enzymatic activity of CT and LT. LTK63 and LTR72 are mutants of LT that are inactive and have significantly reduced ADP-ribosylating activity, respectively. LT mutants have been evaluated as adjuvants for different mucosal immunization routes including oral, nasal, and anogenital routes. Intranasal immunization with LT mutant adjuvants and appropriate vaccine antigens has led to protection against challenge with HSV (137), Bordetella pertussis (138) , and Streptococcus pneumoniae (139) . LT mutants have also been used to adjuvant HIV-1 p55 gag subunit vaccines administered orally and intranasally (140) . In these examples of LT mutant adjuvants, the mechanism of protection was primarily due to induction of potent cytotoxic T lymphocyte responses. The mechanism of action of CT and LT is thought to arise from enhanced permeation of antigens across epithelial barriers and a marked increase in antigen presentation by APCs (141, 142) . Oral vaccines adjuvanted with CT or LT have been implicated in targeting M cells that are responsible for antigen sampling and uptake in intestinal sites (81) .
As discussed above, immunologists have pointed to innate immune receptors as targets for adjuvant activity, and in some cases TLR ligands have been intentionally incorporated into experimental mucosal formulations. For example, bacterial flagellin, a ligand for both TLR5 and the NLR IPAF/NLRC4, exhibits adjuvant activity in mucosal immunization studies. Synthetic ligands for TLR9 (e.g., CpG) are in clinical trials to modify mucosal immune responses to allergens. There is clearly much more work required in this area, as the aforementioned bacterial toxins known to provide adjuvant activity (e.g., CT, LT) have yet to be directly connected to specific innate immune responses. This might suggest that there is additional complexity in immune adjuvant responses that are independent of innate immune signaling pathways, or that the relevant pathways have not been identified. Moreover, the anatomy of the mucosal tissue and regulation of mucosal immunity may also require unique mucosal adjuvants not associated with systemic immune responses.
Finally, as discussed here, vaccine carrier systems have not generally been established with adjuvant activity in mind. A variety of polymers such as PLGA and chitosan have been used in many vaccine formulations for their effects on antigen release and adhesion to mucosal surfaces, but they have not been directly tested for their ability to trigger innate immune receptors. Effective vaccines contain an immunostimulating component, but polymer nanoparticles in some cases can be immunostimulating. Chitosan-based nanoparticles (see above) not only are mucoadhesive but also increase absorption through the mucosa lining because of their intrinsic ability to open tight junctions (143) . Read et al. (144) showed that chitosan particles delivered to mucosal tissues were immunostimulatory, producing cytokines such as interferon γ, sIgA, and IgG. Recently, Baaten et al. (145) showed that chitin-based nanoparticles can boost innate immunity when delivered to NALT by upregulation of cytokines tumor necrosis factor α, interferon γ, and IL-6 postimmunization. These examples raise the possibility that modified versions of these polymers could be developed specifically for stimulation of innate immune receptors such as TLR2 or TLR5, assuming that such modified polymers can retain the physical properties that make them useful as vaccine carriers. In sum, many opportunities for innovation remain, and given the rapid advances in immunology, more rational strategies for adjuvant development should be possible.
